Medical and Pharmaceutical Citi boosts share target for ArriVent BioPharma by US$4 on positive trial data The biotech operator's lung cancer drug enabled 16-month progression-free survival among patients Rowan Dunne1 day ago
Gold Canaccord analyst says gold’s momentum won’t be slowing anytime soon Economic turmoil continues to make the commodity's value ascend Rowan DunneMay 28, 2025